MapLight Therapeutics has completed enrollment in its Phase 2 ZEPHYR trial for schizophrenia and the final patient visit in its Phase 2 IRIS trial for autism spectrum disorder. These trials evaluate the efficacy and safety of ML-007C-MA for schizophrenia and ML-004 for autism. The company expects topline results from both trials by mid-August 2026, marking a key milestone in developing new treatments for these central nervous system disorders. Successful outcomes could address significant unmet medical needs in schizophrenia and autism.
The global Bioprocess Automation Software market, valued at $1.67 billion in 2025, is projected to grow to $6.19 billion by 2035 at a 14% CAGR. This growth is fueled by the increasing demand for personalized medicine, flexible manufacturing processes...
The global microneedle drug delivery systems market is projected to grow from $7.04 billion in 2025 to $14.37 billion by 2035, at a CAGR of 7.4%. Growth is fueled by rising demand for minimally invasive, pain-free, and self-administered drug delivery...
Novartis announced it will present 15 abstracts at the European Renal Association Congress 2026, highlighting late-stage clinical data for kidney disease treatments including Vanrafia (atrasentan), Fabhalta (iptacopan), and zigakibart for IgA nephrop...
Render's token price surged to $2.25, rising 13.16% in 24 hours and 24.16% over a week, driven by a 12-week high in daily active addresses and new wallets. Increased derivatives volume and open interest indicate stronger trader activity, while Render...
XRP slipped below the $1.35 level after failing to break above $1.36, signaling short-term bearish momentum within a tight trading range. Traders are now focused on the critical $1.30 to $1.31 support zone, where a decisive breakdown could lead to fu...
